A prospective study on the prevalence of at‐risk <scp>MASH</scp> in patients with type 2 diabetes mellitus in the United States
Nikita Mittal(University of California San Diego), Rohit Loomba(University of California San Diego), Veeral Ajmera(University of California San Diego), Egbert Madamba(University of California San Diego), Ricki Bettencourt(University of California San Diego), Harris Siddiqi(University of California San Diego), Lisa Richards(University of California San Diego)
Cited by 21
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k